Work

Phase (Ph) 1/2a study of TSR-011, a potent inhibitor of ALK and TRK, in advanced solid tumors including crizotinib-resistant ALK positive non-small cell lung cancer.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8063

Authors: Hendrik-Tobias Arkenau, Jasgit C. Sachdev, Monica M. Mita, Rafal Dziadziuszko, Chia-Chi Lin, James CH Yang, Jeffrey R. Infante, Stephen Patrick Anthony, Mark Voskoboynik, Wu-Chou Su, Javier De Castro, Ronald B. Natale, Zhi-Yi Zhang, Lorraine Hughes, Dmitri Bobilev, Glen J. Weiss

Institutions: Sarah Cannon Research Institute, Cedars-Sinai Medical Center, Gdańsk Medical University, National Taiwan University Hospital, Sarah Cannon, Tennessee Oncology, National Cheng Kung University Hospital, Hospital Universitario La Paz, Tesaro (United States), Western Regional Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2273873960

Cites:

Cited by: 30

Related to: 10